Bruce C. Cozadd

2017

In 2017, Bruce C. Cozadd earned a total compensation of $10.3M as Chairman and CEO at Jazz Pharmaceuticals, a 17% increase compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$961,800
Option Awards$3,669,875
Salary$950,385
Stock Awards$4,711,828
Other$10,722
Total$10,304,610

Cozadd received $4.7M in stock awards, accounting for 46% of the total pay in 2017.

Cozadd also received $961.8K in non-equity incentive plan, $3.7M in option awards, $950.4K in salary and $10.7K in other compensation.

Rankings

In 2017, Bruce C. Cozadd's compensation ranked 609th out of 14,666 executives tracked by ExecPay. In other words, Cozadd earned more than 95.8% of executives.

ClassificationRankingPercentile
All
609
out of 14,666
96th
Division
Manufacturing
201
out of 5,772
97th
Major group
Chemicals And Allied Products
47
out of 2,075
98th
Industry group
Drugs
33
out of 1,731
98th
Industry
Pharmaceutical Preparations
29
out of 1,333
98th
Source: SEC filing on June 15, 2018.

Cozadd's colleagues

We found five more compensation records of executives who worked with Bruce C. Cozadd at Jazz Pharmaceuticals in 2017.

2017

Suzanne Hooper

Jazz Pharmaceuticals

Executive Vice President and GC

2017

Matthew Young

Jazz Pharmaceuticals

Chief Financial Officer

2017

Russell Cox

Jazz Pharmaceuticals

Chief Operating Officer

2017

Karen Smith

Jazz Pharmaceuticals

Chief Marketing Officer

2017

Michael Miller

Jazz Pharmaceuticals

Executive Vice President U.S Commercial

News

You may also like